Clinical Trial Update: Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

BEBT-109 is being studied in a Phase 2 clinical trial for non-small cell lung cancer with EGFR Exon 20 insertion mutations; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• BEBT-109 (BEBT-109)

Snippet

Sponsor: BeBetter Med Inc | Conditions: Non-Small Cell Lung Cancer, EGFR Exon 20 Insertion Mutation | Phase 2 | Status: RECRUITING